Skip to main content

Eric Meyers, John Hallinan, John McCarthy, Eric Lachenmeier

Premium

3rd Millennium of Cambridge, Mass., has promoted Eric Meyers from vice president of marketing and business development to the newly created position of chief operating officer. In this role, Meyers will oversee the company’s new business development, recruitment, partnering, and marketing efforts, in addition to supporting 3rd Millennium’s “aggressive growth initiatives in the coming year,” according to a company statement.

 

AnVil of Burlington, Mass., has hired John Hallinan as CFO and John McCarthy as director of discovery informatics.

Hallinan was previously CFO at Boston-based 3D application provider Animation Technologies. Prior to that, he was the CFO of life science and chemical software firm CambridgeSoft. McCarthy most recently served as director of bioinformatics at Cellomics of Pittsburgh, Pa.

 

Eric Lachenmeier, former vice president of technology development at Incyte Genomics, has been tapped as the new director of business development at San Diego, Calif.-based biochip company Aviva Biosciences. Lachenmeier, who was also the founder and president of Allegro Biosciences and an R&D project leader and engineer at Lynx Therapeutics and Applied Biosystems, will be responsible for Aviva’s fundraising efforts.

Filed under

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.